Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
暂无分享,去创建一个
Nicky J Welton | Patricia Guyot | AE Ades | Mario JNM Ouwens | N. Welton | A. Ades | M. Ouwens | P. Guyot
[1] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[2] H Putter,et al. Meta‐analysis of pairs of survival curves under heterogeneity: A Poisson correlated gamma‐frailty approach , 2009, Statistics in medicine.
[3] Tsiporah Shore,et al. A meta‐analysis of stages I and II Hodgkin's disease , 1990, Cancer.
[4] N. Black. CONSORT , 1996, The Lancet.
[5] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[6] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[7] Timothy L. Lash,et al. Comprar Modern Epidemiology | Timothy L. Lash | 9781451190052 | Lippincott Williams & Wilkins , 2012 .
[8] Z. Philips,et al. Network meta‐analysis of parametric survival curves , 2010, Research synthesis methods.
[9] Stefan Michiels,et al. Meta-analysis when only the median survival times are known: A comparison with individual patient data results , 2005, International Journal of Technology Assessment in Health Care.
[10] Paula R Williamson,et al. Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.
[11] Gaëtan MacGrogan,et al. Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer , 2010, BMC medical research methodology.
[12] Christopher Cox,et al. The generalized F distribution: An umbrella for parametric survival analysis , 2008, Statistics in medicine.
[13] K. Dear,et al. Iterative generalized least squares for meta-analysis of survival data at multiple times. , 1994, Biometrics.
[14] J L Hutton,et al. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. , 2000, Journal of evaluation in clinical practice.
[15] K. Abrams,et al. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study , 2011, BMC medical research methodology.
[16] P. Royston,et al. Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.
[17] JEH-NAN PAN. Evaluating the Gauge Repeatability and Reproducibility for Different Industries , 2006 .
[18] J B Wong,et al. Meta-analysis of failure-time Data with Adjustment for Covariates , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.
[19] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[20] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[21] George A. Wells,et al. An Assessment of Methods to Combine Published Survival Curves , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] James B. McDonald,et al. A generalization of the beta distribution with applications , 1995 .
[23] N. Welton,et al. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] L. Stewart,et al. To IPD or not to IPD? , 2002, Evaluation & the health professions.
[25] J. Neijt,et al. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. , 1989, European journal of cancer & clinical oncology.
[26] Robert B Livingston,et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.
[27] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[28] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[29] Fu-Kwun Wang,et al. Confidence intervals in repeatability and reproducibility using the Bootstrap method , 2003 .
[30] Theo Stijnen,et al. Interim analysis on survival data: its potential bias and how to repair it , 2005, Statistics in medicine.
[31] A Whitehead,et al. A general parametric approach to the meta-analysis of randomized clinical trials. , 1991, Statistics in medicine.
[32] Theo Stijnen,et al. Meta‐analysis of summary survival curve data , 2008, Statistics in medicine.
[33] J. Jansen. Network meta-analysis of survival data with fractional polynomials , 2011, BMC medical research methodology.